Heart Rate Variability to Quantify General Anesthesia Depth
NCT ID: NCT04788732
Last Updated: 2021-03-09
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
200 participants
OBSERVATIONAL
2021-01-04
2022-08-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Heart Rate Variability for Prediction of Perioperative Events
NCT00481234
Accuracy of Cardiac Arrhythmias and Conduction Disorders Diagnosis Using a Smartwatch
NCT04437914
Transcutaneous Carbon-dioxide Monitoring in Electrophysiological Procedures in Deep Sedation
NCT04038476
Heart Rate Variability in Trauma Patients
NCT00795535
REDUCED FUNCTIONALITY AND KINESIOPHOBIA IN PATIENTS WITH HEART FAILURE: USE OF ALTERNATIVE THERAPEUTIC STRATEGIES
NCT07099495
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Anesthesia depth assessment ( DoA: from English, Depth of Anesthesia ) is essential for anesthetic practice. The DoA depends on two opposing factors: the amount of anesthetic agent administered to the patient and the stimuli produced during surgery, increasing the level of awareness, and the patient's nociception. The ideal level d the DoA involves the guaranteed unconsciousness and anti-nociception adequate during surgery without compromise the functions of vital organs. In other words, one of the main challenges for anesthetists is to identify the appropriate amount of anesthetic to be administered to avoid the unwanted effects of anesthetic shortages (leading, for example, to intraoperative awareness) or anesthetic overdose, which can cause severe problems during intra and postoperative periods. 2 Before using muscle relaxants, the appropriate level of DoA could be monitored by the absence of movements to painful stimuli; once, the surgical incision's lack of movements was a sure sign that the patient was not superficially anesthetized. However, with the muscle relaxants' adoption in the anesthetics protocols, other measures to ensure that anesthetic agents' concentrations were administered properly were necessary.
Becoming conscious during surgery is a major concern for patients and anesthesiologists. It is estimated that the incidence of consciousness during general anesthesia is low, around 0.04% to 0.3%. However, considering the high number of surgical interventions, accidental awareness during surgery represents thousands of cases worldwide. Therefore, despite being an old problem, awareness during anesthesia is still a very relevant issue in public health.
DoA inefficient may also lead to an imbalance nociception x anti-nociception intraoperatively, even without patient conscious pain. Nociceptive stimuli can substantially affect the physiological state, inducing, for example, tachycardia, hypertension, nausea, fainting, and, therefore, negatively influencing patients' postoperative period 1 Thus, careful and efficient monitoring of DoA is the key to minimizing both the possibility of accidental awareness in surgeries and the overdose of anesthetic agents. 3 However, despite the importance of monitoring d the DoA, it is not easy to quantify this parameter during general anesthesia, and several approaches have been proposed to accomplish this task.
Quantification of DoA:
The anesthetic depth could be identified by monitoring the sympathetic activity of the patient. However, many anesthetics substantially alter autonomic activity, both sympathetic and parasympathetic. The observation of autonomic responses such as sweating, tear formation, hypertension, tachycardia, and pupil dilation are also important indicators of adequate unconsciousness levels. However, these signals cannot guide the anesthetist, considering that the patient cannot react due to neuromuscular blockade. 3 On the other hand, some authors suggest monitoring the concentration of inspired and expired anesthetic gases as markers of DoA.4 However, to date, there is no standardized and universally accepted method for quantifying DoA, and the anesthesiologist's experience is still the most important and effective factor in determining DoA.
DoA's monitoring techniques have advanced considerably in recent years. The nature of changes in electroencephalographic patterns during the stages of anesthesia was studied in detail, opening up possibilities for monitoring DoA by identifying electroencephalogram (EEG) patterns with crucial clinical significance for anesthesia.5 The use of EEG devices made monitoring of DoA potentially easier and was recommended by NIH - Care Excellence.
Although the progress brought by EEG-based monitors to anesthetic practice is indisputable, they still have significant limitations: 1) the algorithms created to derive a single DoA index from the EEG are exclusive (owned by their creators) for each device; 2) The EEG obtained in these devices is limited, exclusively, to the activity of the frontal lobe, lacking the representation of deeper subcortical structures ; 3) EEG is recognized for being highly sensitive to a variety of sources of interference during monitoring; 4) it is high cost restricts the availability of such equipment. Several monitors have prices ranging from £ 4,687 to £ 10,285 for the initial purchase, followed by the acquisition of single-use sensors ranging from £ 0.56 to £ 14.08. (3) Also, recent studies have pointed to substantial divergences between the most common commercial displays at DoA, making the application of these electronic devices still controversial and not universally recommended. 4 Specific limitations to the use of BIS, such as the inconsistency of this index in some situations, have also been reported. 6 BIS's particular challenge involves the administration of ketamine, nitric oxide, and xenon, which do not produce the typical EEG patterns observed during general anesthesia with other anesthetic agents. Besides, as the BIS was created based on a database of volunteers under specific conditions, it must be revalidated whenever used with a new drug or even a unique patient population, whose characteristics differ from the original population database data.7
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
1-Inhalation Anesthesia
patients in this group will be anesthetized only with an inhaled anesthetic ( Sevoflurane ).
ECG and EEG monitoring
the ECG and EEG will also be monitored during the entire period that the patients remain anesthetized with various anesthetics drugs and will later be used to compose the DoA score based on HRV.
2-Total Intravenous Anesthesia
the patients in this group will be anesthetized with only intravenous drugs such as benzodiazepícos (midazolam), opioids (alfentanil, fentanyl, sufentanil, remifentanil), hypnotics ( propofol and etomidate ), associated or not to relaxing neuromuscular (nondepolarizing/depolarizing), and adjuvant drugs such as dextrocetamina, dexmedetomidine, lidocaine, and magnesium sulfate.
ECG and EEG monitoring
the ECG and EEG will also be monitored during the entire period that the patients remain anesthetized with various anesthetics drugs and will later be used to compose the DoA score based on HRV.
3-Balanced anesthesia
the patients in this group will be anesthetized with blends of anesthetic inhaled (Sevoflurane) and intravenous drugs such as benzodiazepine (midazolam), opioids (alfentanil, fentanyl, sufentanil, remifentanil), hypnotics ( propofol and etomidate ), associated or not with neuromuscular relaxants (nonpolarizing/depolarizing) and adjuvant drugs such as dextrocetamine, dexmedetomidine, lidocaine, and magnesium sulfate.
ECG and EEG monitoring
the ECG and EEG will also be monitored during the entire period that the patients remain anesthetized with various anesthetics drugs and will later be used to compose the DoA score based on HRV.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
ECG and EEG monitoring
the ECG and EEG will also be monitored during the entire period that the patients remain anesthetized with various anesthetics drugs and will later be used to compose the DoA score based on HRV.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* Patients with severe eczema, allergy, or skin atopy.
* Patients with a history of severe autonomic dysfunction.
* Need of autonomic cardiac blockers during the intraoperative period.
* Absence of Consent.
0 Months
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of Sao Paulo
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Waynice N.P. Garcia
Assistant Professor, M.D, Ph.D
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Waynice N. Paula-Garcia
Ribeirão Preto, São Paulo, Brazil
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Role: backup
References
Explore related publications, articles, or registry entries linked to this study.
Guignard B. Monitoring analgesia. Best Pract Res Clin Anaesthesiol. 2006 Mar;20(1):161-80. doi: 10.1016/j.bpa.2005.09.002.
Fahy BG, Chau DF. The Technology of Processed Electroencephalogram Monitoring Devices for Assessment of Depth of Anesthesia. Anesth Analg. 2018 Jan;126(1):111-117. doi: 10.1213/ANE.0000000000002331.
Smith A. Literature review: Awareness of anaesthesia. J Perioper Pract. 2017 Sep;27(9):191-195. doi: 10.1177/175045891702700903.
Merry AF, Cooper JB, Soyannwo O, Wilson IH, Eichhorn JH. International Standards for a Safe Practice of Anesthesia 2010. Can J Anaesth. 2010 Nov;57(11):1027-34. doi: 10.1007/s12630-010-9381-6. Epub 2010 Sep 21. No abstract available.
Shander A, Lobel GP, Mathews DM. Brain Monitoring and the Depth of Anesthesia: Another Goldilocks Dilemma. Anesth Analg. 2018 Feb;126(2):705-709. doi: 10.1213/ANE.0000000000002383. No abstract available.
Hajat Z, Ahmad N, Andrzejowski J. The role and limitations of EEG-based depth of anaesthesia monitoring in theatres and intensive care. Anaesthesia. 2017 Jan;72 Suppl 1:38-47. doi: 10.1111/anae.13739.
Kissin I. Depth of anesthesia and bispectral index monitoring. Anesth Analg. 2000 May;90(5):1114-7. doi: 10.1097/00000539-200005000-00021. No abstract available.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CAAE: 33066620.1.0000.5440
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.